Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE)

Max Kates, Xiangying Chu, Noah M. Hahn, Eugene J. Pietzak, Angela B. Smith, Daniel H. Shevrin, Paul L. Crispen, Stephen B. Williams, Siamak Daneshmand, Vignesh T. Packiam, Sima P. Porten, Mary E. Westerman, Lynne I. Wagner, Michael A. Carducci